Who Owns Lucentis?
Lucentis is owned by Novartis, a publicly traded Swiss multinational pharmaceutical company. Lucentis is Novartis's eye disease treatment. Novartis is headquartered in Basel, Switzerland and trades on SIX (NOVN) and NASDAQ (NVS).
Parent Company
Novartis
Founded
2006
Status
Publicly Traded
Headquarters
Basel, Switzerland
Who Owns Lucentis?
- Parent Company: Novartis
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: SIX: NOVN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Lucentis | Novartis | Wholly owned |
History of Lucentis
- Founded: 2006
- Founders: Novartis (internal development)
Lucentis was developed by Novartis through extensive research into vascular endothelial growth factor inhibition for treating eye diseases. The drug was approved by the FDA in 2006 as a treatment for age-related macular degeneration. Lucentis represented a significant breakthrough in ophthalmology, offering patients a treatment that could slow vision loss from AMD.
The development of Lucentis involved years of research into VEGF pathway inhibition in the eye. Novartis conducted extensive clinical trials demonstrating the drug's efficacy in improving or stabilizing vision in AMD patients. Lucentis quickly became one of the most prescribed treatments for age-related macular degeneration globally.
Following its initial approval for AMD, Lucentis was approved for additional indications including diabetic retinopathy and retinal vein occlusion. The drug's expanded label allowed it to serve a broader patient population with various retinal diseases. Lucentis became one of Novartis's most successful ophthalmology products.
In recent years, Lucentis has continued to maintain its position as a leading treatment for retinal diseases. The drug has been approved in numerous countries worldwide and has become a standard therapy for age-related macular degeneration and diabetic retinopathy. Lucentis remains one of the leading eye disease medications in the market.
About Novartis
What does Novartis own?
Novartis owns a portfolio of innovative prescription medicines across oncology, immunology, cardiovascular, neuroscience, and ophthalmology. Key products include Cosentyx (inflammatory diseases), Entresto (heart failure), Kisqali (breast cancer), Kesimpta (multiple sclerosis), Leqvio (cholesterol), Zolgensma (gene therapy for spinal muscular atrophy), and Kymriah (CAR-T cell therapy). Novartis spun off its Sandoz generics division in 2023 and its Alcon eye care division in 2019.
Is Novartis publicly traded?
Yes, Novartis AG is listed on the SIX Swiss Exchange under ticker NOVN and on NASDAQ under ticker NVS (as American Depositary Receipts). The company has a broad institutional and retail shareholder base with no single controlling shareholder. Major institutional shareholders include Vanguard Group and BlackRock.
Who founded Novartis?
Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two of Switzerland's oldest pharmaceutical companies. Ciba-Geigy itself was formed through the 1970 merger of Ciba and Geigy, both founded in Basel in the 19th century. Sandoz was founded in 1886 in Basel. The 1996 merger was one of the largest corporate mergers in history at the time, valued at approximately $63 billion.
Where is Novartis headquartered?
Novartis AG is headquartered in Basel, Switzerland. Basel has been the center of the Swiss pharmaceutical industry for more than a century, and Novartis, Roche, and several other major pharmaceutical companies are headquartered in the city. Novartis operates manufacturing and research facilities in Switzerland, the United States, Germany, Spain, Italy, Japan, China, India, Singapore, and Brazil.
How many products does Novartis sell?
Novartis sells dozens of prescription medicines across multiple therapeutic areas. The company's growth portfolio is led by Cosentyx, Entresto, Kisqali, Kesimpta, Leqvio, Zolgensma, and Kymriah. Novartis has a pipeline of more than 150 projects in clinical development across its therapeutic focus areas. The company sells products in more than 140 countries worldwide.
Who owns Novartis?
Novartis AG is publicly traded on the SIX Swiss Exchange and NASDAQ with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. The Novartis Foundation for Employee Participation holds a significant stake. Major institutional shareholders include Vanguard Group and BlackRock. Vas Narasimhan serves as CEO and Joerg Reinhardt chairs the board.
- Founded: 1996
- Headquarters: Basel, Switzerland
- Company Type: Publicly Traded
- Stock: SIX: NOVN
Where Is Lucentis Made / Based?
- Headquarters: Basel, Switzerland
- Manufacturing / Operations: Switzerland, Germany, United States
Brands Owned by Novartis
- Afinitor - Prescription oncology medication for treating various cancers including renal ce...
- Alcon - Global leader in eye care products and surgical equipment, specializing in conta...
- Cosentyx - Prescription biologic medication for treating autoimmune diseases including psor...
- Exelon - Brand name for rivastigmine, a prescription cholinesterase inhibitor developed b...
- Gilenya - Prescription immunosuppressant medication for treating relapsing-remitting multi...
- Lamisil - Over-the-counter antifungal medication for treating fungal infections including ...
- Otrivin - Over-the-counter nasal decongestant spray for relieving nasal congestion from co...
- Sandoz - Independent global leader in generic and biosimilar pharmaceuticals, spun off fr...
- Tasigna - Prescription oncology medication for treating chronic myeloid leukemia, owned by...
- Theraflu - Over-the-counter cold and flu relief medication combining multiple active ingred...
- Voltaren - Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owne...
Lucentis Ownership: Pros & Cons
Advantages
- +Effective VEGF inhibitor for age-related macular degeneration
- +Proven efficacy in improving or stabilizing vision in AMD patients
- +Approved for multiple retinal disease indications
- +Backed by extensive clinical research and safety data
- +Supported by Novartis's research capabilities and pharmaceutical expertise
- +Available globally with established distribution networks
- +Improved vision outcomes for patients with retinal diseases
Considerations
- -High cost as a biologic eye disease medication
- -Requires regular intravitreal injections
- -Potential for serious eye complications including infection
- -Requires monitoring by ophthalmologists
- -Not suitable for patients with certain eye conditions
- -Competition from other anti-VEGF treatments
- -Potential for adverse reactions in some patients
Frequently Asked Questions About Lucentis
Where to Buy
Disclosure: We may earn commission from purchases
Lucentis on AmazonNovartis Stock Information
Jobs at Novartis
Latest News About Lucentis
Related Articles About Lucentis
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Monthly M&A Roundup: February 2026 Brand Ownership Changes
From Keurig Dr Pepper's planned split to the Netflix-WBD saga, here is every major brand ownership change and deal in February 2026.
The Most Acquired Categories: Tech vs CPG vs Pharma
Which industries see the most brand acquisitions? We compared technology, consumer goods, and pharmaceuticals to find out where the most M&A activity happens and why.